Sharing Services Global holder reports 99.9% stake

Sharing Services Global Corp shareholder group led by Heng Fai Ambrose Chan files an amended Schedule 13D reporting beneficial ownership of 131,767,623 shares, or 99.9% of the common stock, based on 309,652 shares outstanding as of March 24, 2026.

Rhea-AI Filing Summary

Sharing Services Global Corp shareholder group led by Heng Fai Ambrose Chan files an amended Schedule 13D reporting beneficial ownership of 131,767,623 shares, or 99.9% of the common stock, based on 309,652 shares outstanding as of March 24, 2026.

On February 4, 2026, the issuer issued a $125,000 convertible promissory note to HWH International Inc. at $0.006 per share, convertible into common stock at HWH’s option for three years. The filing outlines Mr. Chan’s roles across several affiliated entities that collectively hold the reported securities and notes that the reporting persons may discuss business, governance, or capital structure matters with the company and may acquire or dispose of additional securities.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What ownership stake in SHRG does Heng Fai Ambrose Chan report in this Schedule 13D/A?

The filing reports beneficial ownership of 131,767,623 shares of Sharing Services Global Corp, representing 99.9% of the common stock based on 309,652 shares outstanding as of March 24, 2026. This reflects holdings across multiple entities controlled by Heng Fai Ambrose Chan.

What new security did Sharing Services Global Corp issue that triggered this SHRG Schedule 13D/A amendment?

On February 4, 2026, Sharing Services Global Corp issued a convertible promissory note to HWH International Inc. The note has a principal amount of $125,000 and is convertible at $0.006 per share into the company’s common stock at HWH’s option for three years.

Which entities related to Heng Fai Ambrose Chan hold SHRG securities in this 13D/A filing?

The filing lists Heng Fai Holdings Limited, Alset Inc., HWH International Inc., Alset International Limited, Global Biomedical Pte. Ltd., and Mr. Chan personally. Due to his roles and control over these entities, Mr. Chan is deemed to beneficially own their Sharing Services Global Corp holdings.

How does Alset Inc. report its beneficial ownership of SHRG common stock?

Alset Inc. reports beneficial ownership of 131,726,639 shares of Sharing Services Global Corp common stock, or 99.8% of the class, based on 309,652 shares outstanding as of March 24, 2026. This total includes shares issuable from debt and warrants held through affiliated entities.

What intentions toward Sharing Services Global Corp do the reporting persons describe in this SHRG Schedule 13D/A?

The reporting persons state they may discuss with the board, management, or other stockholders topics such as acquisitions or dispositions of securities, and potential changes to business, operations, governance, strategy, or capitalization. They may also acquire additional securities in various types of transactions.

What are the key terms of HWH International Inc.’s SHRG-related holdings in this filing?

HWH International Inc. holds debt and warrants of Sharing Services Global Corp convertible into 129,136,906 shares of common stock. It also received a $125,000 convertible promissory note on February 4, 2026, convertible at $0.006 per share for three years at HWH’s option.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/24/2026 - 04:05 PM EDT Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 7)

SHARING SERVICES GLOBAL Corp

(Name of Issuer)

COMMON STOCK, $0.0001 PAR VALUE

(Title of Class of Securities)

819536103

(CUSIP Number)

Chan Heng Fai
9 Temasek Boulevard #16-04, Suntec Tower Two
Singapore, U0, 038989
011 65 6333 9181

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

02/04/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

schemaVersion:

SCHEDULE 13D

CUSIP Number(s): 819536103

1

Name of reporting person

Heng Fai Ambrose Chan

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

SINGAPORE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 40,984.00
8	Shared Voting Power 131,767,623.00
9	Sole Dispositive Power 40,984.00
10	Shared Dispositive Power 131,767,623.00

11

Aggregate amount beneficially owned by each reporting person

131,767,623.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

99.9 %

14

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person:

Mr. Heng Fai Ambrose Chan; Heng Fai Holdings Limited; Alset Inc.; HWH International Inc.; Alset International Limited; and Global Biomedical Pte. Ltd. are members of a group for the purpose of this Schedule 13D. The figure set forth above includes (i) 86 shares held by Heng Fai Holdings Limited; (ii) 2,550,305 shares held by Alset Inc. (including debt of the Issuer which may be converted into 2,500,000 shares of the Issuer's common stock); (iii) debt and warrants of the Issuer held by HWH International Inc., which may be converted into 129,136,906 shares of the Issuer; (iv) 30,524 shares held by Alset International Limited; (v) 8,904 shares held by Global Biomedical Pte. Ltd.; and (vi) 40,274 shares held by Mr. Chan personally. Mr. Heng Fai Ambrose Chan is: (i) the sole director and sole shareholder of Heng Fai Holdings Limited; (ii) the Chief Executive Officer and Chairman of the Board of Directors of Alset Inc.; (iii) the Chief Executive Officer and Chairman of the Board of Directors of HWH International Inc.; (iv) the group Chief Executive Officer of Alset International Limited; and (v) Director of Global Biomedical Pte. Ltd. Accordingly, due to his interest in, and control over these entities, Mr. Chan indirectly holds beneficial interest in shares of the Issuer owned by such entities, and can exercise common control over the voting powers of these shares of the Issuer. This percentage is calculated based upon 309,652 outstanding shares of the Issuer as of March 24, 2026.

SCHEDULE 13D

CUSIP Number(s): 819536103

1

Name of reporting person

Heng Fai Holdings Limited

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

HONG KONG

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 86.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 86.00

11

Aggregate amount beneficially owned by each reporting person

86.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0 %

14

Type of Reporting Person (See Instructions)

CO

Comment for Type of Reporting Person:

Mr. Heng Fai Ambrose Chan; Heng Fai Holdings Limited; Alset Inc.; HWH International Inc.; Alset International Limited; and Global Biomedical Pte. Ltd. are members of a group for the purpose of this Schedule 13D. Mr. Heng Fai Ambrose Chan is the sole director and sole shareholder of Heng Fai Holdings Limited, accordingly, due to his interest in, and control over Heng Fai Holdings Limited, Mr. Chan indirectly holds beneficial interest in shares of the Issuer owned by Heng Fai Holdings Limited, and can exercise common control over the voting powers of these shares of the Issuer. This percentage is calculated based upon 309,652 outstanding shares of the Issuer as of March 24, 2026.

SCHEDULE 13D

CUSIP Number(s): 819536103

1

Name of reporting person

Alset Inc.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

TEXAS

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 131,726,639.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 131,726,639.00

11

Aggregate amount beneficially owned by each reporting person

131,726,639.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

99.8 %

14

Type of Reporting Person (See Instructions)

CO

Comment for Type of Reporting Person:

Mr. Heng Fai Ambrose Chan; Heng Fai Holdings Limited; Alset Inc.; HWH International Inc.; Alset International Limited; and Global Biomedical Pte. Ltd. are members of a group for the purpose of this Schedule 13D. Comprises (i) 2,550,305 shares held by Alset Inc. (including debt of the Issuer which may be converted into 2,500,000 shares of the Issuer's common stock); (ii) debt and warrants of the Issuer held by HWH International Inc., which may be converted into 129,136,906 shares of the Issuer; (iii) 30,524 shares held by Alset International Limited; and (iv) 8,904 shares held by Global Biomedical Pte. Ltd. Alset Inc. has voting and dispositive control over HWH International Inc., Alset International Limited and Global Biomedical Pte. Ltd. This percentage is calculated based upon 309,652 outstanding shares of the Issuer as of March 24, 2026.

SCHEDULE 13D

CUSIP Number(s): 819536103

1

Name of reporting person

HWH International Inc.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 129,136,906.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 129,136,906.00

11

Aggregate amount beneficially owned by each reporting person

129,136,906.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

99.8 %

14

Type of Reporting Person (See Instructions)

CO

Comment for Type of Reporting Person:

Mr. Heng Fai Ambrose Chan; Heng Fai Holdings Limited; Alset Inc.; HWH International Inc.; Alset International Limited; and Global Biomedical Pte. Ltd. are members of a group for the purpose of this Schedule 13D. Comprises debt and warrants of the Issuer held by HWH International Inc. convertible into 129,136,906 shares of the Issuer's common stock. This percentage is calculated based upon 309,652 outstanding shares of the Issuer as of March 24, 2026.

SCHEDULE 13D

CUSIP Number(s): 819536103

1

Name of reporting person

Alset International Limited

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

SINGAPORE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 39,428.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 39,428.00

11

Aggregate amount beneficially owned by each reporting person

39,428.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

12.7 %

14

Type of Reporting Person (See Instructions)

CO

Comment for Type of Reporting Person:

Mr. Heng Fai Ambrose Chan; Heng Fai Holdings Limited; Alset Inc.; HWH International Inc.; Alset International Limited; and Global Biomedical Pte. Ltd. are members of a group for the purpose of this Schedule 13D. Comprises (i) 30,524 shares held by Alset International Limited, and (ii) 8,904 shares held by Global Biomedical Pte. Ltd. Alset International Limited has voting and dispositive control over Global Biomedical Pte. Ltd. This percentage is calculated based upon 309,652 outstanding shares of the Issuer as of March 24, 2026.

SCHEDULE 13D

CUSIP Number(s): 819536103

1

Name of reporting person

Global Biomedical Pte. Ltd.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

SINGAPORE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 8,904.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 8,904.00

11

Aggregate amount beneficially owned by each reporting person

8,904.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

2.8 %

14

Type of Reporting Person (See Instructions)

CO

Comment for Type of Reporting Person:

Mr. Heng Fai Ambrose Chan; Heng Fai Holdings Limited; Alset Inc.; HWH International Inc.; Alset International Limited; and Global Biomedical Pte. Ltd. are members of a group for the purpose of this Schedule 13D. This percentage is calculated based upon 309,652 outstanding shares of the Issuer as of March 24, 2026.

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: COMMON STOCK, $0.0001 PAR VALUE
(b)	Name of Issuer: SHARING SERVICES GLOBAL Corp
(c)	Address of Issuer's Principal Executive Offices: 5200 TENNYSON PKWY #400, Plano, TEXAS , 75024.
Item 2.	Identity and Background
(a)	Heng Fai Ambrose Chan
(b)	9 Temasek Boulevard #16-04, Suntec Tower Two, Singapore 038989
(c)	Chief Executive Officer - Alset International Limited
(d)	None.
(e)	None.
(f)	Singapore
Item 3.	Source and Amount of Funds or Other Consideration
	The information set forth in Item 4 hereof is incorporated by reference in its entirety into this Item 3.
Item 4.	Purpose of Transaction
	On February 4, 2026, the Issuer issued a convertible promissory note to HWH International Inc. ("HWH") in the amount of $125,000. This note is convertible into the Issuer's common stock at $0.006 per share at HWH's option until the maturity of the convertible note three (3) years from the date thereof. Mr. Heng Fai Ambrose Chan ("Mr. Chan") is: (i) the sole Director and sole Shareholder of Heng Fai Holdings Limited; (ii) the Chief Executive Officer and Chairman of the Board of Directors of Alset Inc.; (iii) the Chairman of the Board of Directors and Chief Executive Officer of HWH International Inc.; (iv) the Group Chief Executive Officer of Alset International Limited; and (v) the Director of Global Biomedical Pte. Ltd. Accordingly, due to his interest in, and control over these entities, Mr. Chan indirectly holds beneficial interest in shares of the Issuer's common stock owned by such entities, and can exercise common control over the voting powers of these shares. The Reporting Persons, either directly or indirectly through Mr. Chan, may engage in discussions from time to time with the Issuer's Board of Directors, the Issuer's management or the Issuer's other stockholders. These discussions may be with respect to (i) acquiring or disposing of the shares of Common Stock or other securities of the Issuer; (ii) maintaining or changing the Issuer's business, operations, governance, management, strategy or capitalization; or (iii) implementing transactions that may relate to or may result in any matter set forth in paragraphs (a) through (j) of Item 4 of Schedule 13D. Additionally, the Reporting Persons may acquire additional securities of the Issuer through open market transactions, privately negotiated transactions or other methods. Except as described in Item 6 and this Item 4 and any plans or proposals that may from time to time be discussed or considered by the directors of the Issuer, including Mr. Chan in his fiduciary capacity as a director of the Issuer, the Reporting Persons do not currently have any plans or proposals that relate to or would result in any of the actions specified in in paragraphs (a) through (j) of Item 4 of Schedule 13D. The Reporting Persons intend to review their investment in the Issuer from time to time on the basis of various factors, including the Issuer's business, financial condition, results of operations and prospects, general economic and industry conditions, the securities markets in general and those for the Issuer's stock in particular, as well as other developments.
Item 5.	Interest in Securities of the Issuer
(a)	The information set forth in rows 7 through 13 of the cover pages to this Schedule 13D is incorporated by reference. The percentage set forth in row 13 is based on 309,652 shares of Common Stock outstanding as of March 24, 2026, as reported by the Issuer to the Reporting Persons. The percentages of beneficial ownership were determined in accordance with Rule 13d-3 of the Securities Exchange Act of 1934, as amended. Information with respect to all transactions in the Shares beneficially owned by the Reporting Persons that were effected during the past sixty days is set forth in Item 4 and incorporated herein by reference.
(b)	The information set forth in rows 7 through 13 of the cover pages to this Schedule 13D is incorporated by reference. The percentage set forth in row 13 is based on 309,652 shares of Common Stock outstanding as of March 24, 2026, as reported by the Issuer to the Reporting Persons. The percentages of beneficial ownership were determined in accordance with Rule 13d-3 of the Securities Exchange Act of 1934, as amended. Information with respect to all transactions in the Shares beneficially owned by the Reporting Persons that were effected during the past sixty days is set forth in Item 4 and incorporated herein by reference.
(c)	There were no other transactions effected in the last 60 days by the Reporting Person except for the transactions which are the subject of this Schedule 13D.
(d)	Not applicable.
(e)	Not applicable.
Item 6.	Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
	The information set forth in Item 4 hereof is incorporated by reference in its entirety into this Item 6. Other than the relationship as set out in Item 4 hereof, there are no other contracts, arrangements, understandings or relationships with respect to the Issuer's securities, among the Reporting Persons.
Item 7.	Material to be Filed as Exhibits.
	Exhibit 99.1 - Joint Filing Agreement dated January 28, 2025

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Heng Fai Ambrose Chan

Signature:	/s/ Heng Fai Ambrose Chan
Name/Title:	Heng Fai Ambrose Chan/An individual
Date:	03/24/2026

Heng Fai Holdings Limited

Signature:	/s/ Heng Fai Ambrose Chan
Name/Title:	Heng Fai Ambrose Chan, Director
Date:	03/24/2026

Alset Inc.

Signature:	/s/ Heng Fai Ambrose Chan
Name/Title:	Heng Fai Ambrose Chan/Chief Executive Officer
Date:	03/24/2026

HWH International Inc.

Signature:	/s/ Rongguo Wei
Name/Title:	Rongguo Wei/Chief Financial Officer
Date:	03/24/2026

Alset International Limited

Signature:	/s/ Heng Fai Ambrose Chan
Name/Title:	Heng Fai Ambrose Chan/Chief Executive Officer
Date:	03/24/2026

Global Biomedical Pte. Ltd.

Signature:	/s/ Heng Fai Ambrose Chan
Name/Title:	Heng Fai Ambrose Chan/Director
Date:	03/24/2026